| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | -45.5 | -38.8 |
| EPS (diluted, $ a share) | $-1.86 | $-2.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -80.0% |
|---|
10-Q filed with the SEC, NASDAQ: LYEL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lyell Immunopharma, Inc.: key numbers
- Share price
- $14.65Close, Nov 16
- Market cap
- $360M
- Shares outstanding
- 24.59MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lyell Immunopharma, Inc.
All →Lyell Immunopharma Insider ARCH Venture Partners IX LLC Buys $25M of Stock
ARCH Venture Partners IX LLC bought 2,321,262 shares of Lyell Immunopharma, Inc. at $10.77 a share, worth $25M in total on Nov 4, 2026. Shares held after the trade: 3,747,790 (+162.7%).
- Value
- $25M
- Shares
- 2,321,262
- Price
- $10.77
- Holding change
- +162.7%
- Trade date
- Nov 4, 2026
Lyell Immunopharma Insider ARCH Venture Fund XIII L.P. Buys $25M of Stock
ARCH Venture Fund XIII L.P. bought 2,321,262 shares of Lyell Immunopharma, Inc. at $10.77 a share, worth $25M in total on Nov 4, 2026. Shares held after the trade: 3,747,790 (+162.7%).
- Value
- $25M
- Shares
- 2,321,262
- Price
- $10.77
- Holding change
- +162.7%
- Trade date
- Nov 4, 2026
Lyell Immunopharma Financial Results
Lyell Immunopharma reported Q3 2026 financial results and provided clinical updates for its CAR T-cell therapy ronde-cel, which showed a 91% overall response rate in the PiNACLE trial. The company also announced an $80 million private placement financing, extending its cash runway into 2028.
“The updated ronde-cel data accepted for presentation at ASH further strengthen our conviction in ronde-cel’s potential to meaningfully improve outcomes for patients with large B-cell lymphoma. The high rates of very durable complete responses achieved by ronde-cel in both the second- and third- or later-line settings, including in patients with high-risk primary refractory disease, clearly showcase the next-generation potential of ronde-cel.”
Lynn Seely, M.D., President and Chief Executive Officer of Lyell
Lyell Immunopharma Capital Raise of $80M
Lyell Immunopharma entered into a securities purchase agreement to raise $80.0 million through a private placement of 7,428,040 shares of common stock. The shares were sold to institutional accredited investors at a price of $10.77 per share, with the company agreeing to file a resale registration statement within 30 days of closing.
- Value
- $80M
- Counterparty
- institutional accredited investors